Digestive Disease Week 2026: key results and trends
What the 5,104 abstracts at Digestive Disease Week 2026 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated.
- abstracts
- 5,104
- drug-linked abstracts
- 1,218
- companies
- 221
- from Phase 3 studies
- 64
Drug-linked abstracts by phase
- Phase 1 12
- Phase 1/2 4
- Phase 2 26
- Phase 2/3 4
- Phase 3 64
- Phase 4 3
Key results
Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue
obefazimod
Improvements in patient-reported fatigue among patients with moderately to severely active ulcerative colitis (UC) treated with obefazimod: pooled results from the 8-WEEK ABTECT-1 and ABTECT-2 phase 3 double-blind, placebo-controlled induction trials
Read the abstract (opens in a new tab)At Week 8, a greater proportion of Obe patients had a remission of FACIT-F: 22.2% for Obe-50 and 28.3% for Obe-25 vs 13.4% for PBO (Obe-50:Δ9.0, p<0.05 and Obe-25:Δ14.6, p=0.001).
guselkumab
Symptomatic improvement with intravenous guselkumab induction therapy is observed early in patients with moderately to severely active ulcerative colitis: post-hoc analysis of QUASAR
Read the abstract (opens in a new tab)With SC induction (ASTRO), 35.8% of SC GUS vs 25.9% of PBO pts were in symptomatic response at W2; 12.2% vs 7.9%, respectively, were in symptomatic remission.
mirikizumab
Mirikizumab is efficacious in moderately to severely active Crohn’s Disease after one prior anti-TNF failure
Read the abstract (opens in a new tab)At W52, a statistically significantly higher proportion of mirikizumab-treated participants achieved CDAI remission–composite (mirikizumab: 44.0%; placebo: 15.5%; P<0.001) and endoscopic response–composite (mirikizumab: 37.1%; placebo: 6.9%; P<0.001) compared with placebo.
dupilumab
Combined histologic, endoscopic, and symptomatic remission in adults and adolescents with eosinophilic esophagitis through dupilumab treatment: A post-hoc analysis of the phase 3 LIBERTY EoE TREET study
Read the abstract (opens in a new tab)The proportion of patients achieving combined histologic–endoscopic-symptomatic remission with dupilumab vs placebo was 21.3% vs 1.7% at W24, with all patients in Part C receiving dupilumab; the proportions at W52 were 24.6% (dupilumab–dupilumab) and 21.6% (placebo–dupilumab).
brivekimig
Efficacy and safety of brivekimig (a dual-target, anti-tumour necrosis factor and anti-OX40 ligand NANOBODY®) in participants with moderate-to-severe hidradenitis suppurativa: implications for inflammatory bowel diseases
Read the abstract (opens in a new tab)W16 HiSCR50 median response rates were 67% (brivekimig, N=48) and 37% (placebo, N=23).
PL8177
Safety, tolerability, and efficacy of PL8177 in adults with active ulcerative colitis: results from a phase 2A, randomized, placebo-controlled study
Read the abstract (opens in a new tab)Clinical remission was achieved by 3 of 9 participants (33%) in the PL8177 group (vs none with placebo), while symptomatic remission was achieved by 5 of 9 (56%) with PL8177 (vs 1 of 3 [33%] with placebo).
EBX-102-02
A randomised double-blind placebo-controlled phase II trial assessing the safety and efficacy of EBX-102-02, an oral full-spectrum intestinal microbiota product in patients with irritable bowel syndrome with constipation and diarrhoea; the TrIuMPH trial
Read the abstract (opens in a new tab)At Week 7, mean (SE) IBS-SSS reduction was 61 (15) points with EBX-102-02 compared with 38 (17) points for placebo.
volixibat
Volixibat leads to improvements in fatigue and sleep for adults with primary biliary cholangitis: data from VANTAGE
Read the abstract (opens in a new tab)A higher proportion of VLX-treated participants reported normal/mild fatigue and sleep disturbances after 28 weeks of treatment compared to BL (Fatigue: BL: 8/14, W 28: 10/14; Sleep: BL: 10/14, W28: 13/14), with minimal changes in PBO-treated participants.
garutadustat
ISM5411, a novel gut-restricted PHD1/2 inhibitor for inflammatory bowel disease: a randomized, double-blind, placebo-controlled, first-in-human Phase I study to evaluate safety, tolerability and PK profiles
Read the abstract (opens in a new tab)The incidence of TEAEs was 25.0% and 55.0% in the ISM5411 pooled cohort (n=56) and placebo cohort (n=20), respectively.
Trends at DDW 2026
Small molecules were the most frequent modality (62% of drug-linked abstracts). GLP1R was the most frequent target (7%). Autoimmune colitis was the most frequent disease (20%).
What the abstracts covered
Share of the 1,218 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.
- Bispecific antibodies3%39 drug-linked abstracts
- GLP-1 receptor drugs7%89 drug-linked abstracts
Top targets
- GLP1R897%
- IL23A686%
- TNFA555%
- GR494%
- α4β7494%
- ITGA4474%
- ITGB7474%
- JAK1474%
- ATP4A403%
- IL12B302%
Top modalities
- Small molecules75062%
- Monoclonal antibodies29524%
- Peptides14212%
- Carbohydrate, lipid and polymer therapeutics887%
- Non-antibody therapeutic proteins655%
- Microbial and phage therapeutics575%
- Bispecific antibodies393%
- Natural-product mixtures and botanicals393%
Top diseases
- Autoimmune colitis24320%
- Crohn's disease21017%
- Inflammatory bowel disease (IBD)17614%
- Obesity776%
- Cirrhosis555%
- Colorectal cancer (CRC)464%
- Colitis454%
- Type 2 diabetes mellitus (T2DM)444%
- Metabolic dysfunction-associated steatotic liver disease (MASLD)403%
- Eosinophilic esophagitis (EoE)383%
Most active companies
- Johnson & Johnson1018%
- Takeda887%
- AbbVie696%
- Novo Nordisk676%
- Pfizer635%
- Eli Lilly474%
- Merck373%
- Bristol Myers Squibb353%
- Bayer282%
- GSK232%
Explore every DDW 2026 result in Gosset
All 1,218 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.
This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.